IMMUNOTHERAPIES
Resectable NSCLCImmunotherapies
Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% with chemotherapy alone in KEYNOTE-671
Read the article
Martin Reck
LungenClinic Grosshansdorf
Prof. Martin Reck heads the Department of Thoracic Oncology at LungenClinic Grosshansdorf in Germany. He has led pivotal first-line immunotherapy trials in metastatic NSCLC, including KEYNOTE-024, and continues to drive evidence generation across the lung cancer treatment landscape. He is a frequent speaker at major international congresses.
Connect
Martin Reck
Featured in
Aug
02
2026
D. Rodríguez-AbreuM. Reck
Jul
14
2026
ADCs
Advanced NSCLCADCs
Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date
Read the article
M. HochmairG. MountziosA. AddeoM. Reck
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
